Non-Vitamin K Oral Anticoagulants (NOACs) A Review of Clinical Management and Laboratory Issues

Author(s): Andrew Blann.

Journal Name: Current Vascular Pharmacology

Volume 14 , Issue 3 , 2016

Become EABM
Become Reviewer

Abstract:

The non-vitamin K oral anticoagulants (NOACs) are set to replace vitamin K antagonists (principally warfarin), unfractionated heparin and low molecular weight heparin as the leading antithrombotic prophylaxis in several medical and surgical settings. As a group, NOACs have a better safety profile and at least an equivalent (and sometimes superior) efficacy profile than their comparator. The objective of this review is to provide the practitioner with a comprehensive, balanced and contemporary view of these drugs and their applications. More specifically, it focuses on the evidence base for their licences, use in clinical practice (such as in renal dysfunction, orthopaedic surgery, atrial fibrillation, and venous thromboembolism, and the effects of co-medications), responses to actual or perceived haemorrhage, and the role of the laboratory.

Keywords: NOACs, dabigatran, rivaroxaban, apixaban, edoxaban.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 3
Year: 2016
Page: [220 - 236]
Pages: 17
DOI: 10.2174/1570161113666150610093255
Price: $65

Article Metrics

PDF: 40
HTML: 4
EPUB: 1
PRC: 1

Special-new-year-discount